But how different is ACU193 really?
But subgroup analyses from Trailblazer-Alz 2 show that earlier is better for donanemab.
The Belgian group is riding high as investors look for future successes in other inflammatory diseases.
A convincing hit puts approval, and potentially partnerships, on the table.
But relapses are still frequent – a problem that, curiously, higher dosing has not assuaged.
In the second quarter it paid to be a leading obesity company. As for Covid, not so much.
But large gains for some big pharma players flatter the overall figures.
Without full placebo data, it is hard to handicap VRDN-001’s chances in thyroid eye disease.